Skip to main content
. 2011 Oct 21;16(11):1535–1546. doi: 10.1634/theoncologist.2011-0165

Table 4.

First-line monotherapy targeted agent trials in HER-2+ metastatic breast cancer patients

graphic file with name onc01111-0901-t04.jpg

CBR was defined as complete responses plus partial responses plus stable disease at 6 months in the trastuzumab trials, and at 24 weeks in the lapatinib and neratinib trials.

Abbreviations: CBR, clinical benefit rate; HER-2, human epidermal growth factor receptor 2; ORR, objective response rate.